Sossana Delimpasi

A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis

Efstathios Kastritis, Evangelos Terpos, Maria Gavriatopoulou et al. · Blood · 2012 · 90 citations

Preserved levels of uninvolved immunoglobulins are independently associated with favorable outcome in patients with symptomatic multiple myeloma

Efstathios Kastritis, Flora Zagouri, Argiris Symeonidis et al. · Leukemia · 2014 · 75 citations

Hematological Malignancy, Medicine, Immunology +8

Treatment with bortezomib‐based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group

Eirini Katodritou, Evangelos Terpos, Charikleia Kelaïdi et al. · American Journal of Hematology · 2013 · 68 citations · Full text

Hematological Malignancy, Bortezomib‐based Regimens, Transplantation +15

Re‐evaluation of prognostic markers including staging, serum free light chains or their ratio and serum lactate dehydrogenase in multiple myeloma patients receiving novel agents

Dimitrios Maltezas, Meletios Α. Dimopoulos, Irene Katodritou et al. · Hematological Oncology · 2012 · 64 citations

Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom's macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH)

Efstathios Kastritis, Marie‐Christine Kyrtsonis, Evdoxia Hadjiharissi et al. · Leukemia Research · 2010 · 59 citations

Biomarker (Medicine), Prognostic Biomarkers, Prognosis +7